细胞色素氧化酶CYP2C9基因多态性与个体化治疗  

Individualized Drug Therapy and Gene Polymorphism of CYP2C9

作　　者：李惠芬[1] 孟英韬[1] 

机构地区：[1]天津市儿童医院儿研所,天津300074

出　　处：《医学综述》2011年第3期351-353,共3页Medical Recapitulate

摘　　要：细胞色素氧化酶2C9(CYP2C9)是人类肝脏中一种重要药物代谢酶,代谢约10%的临床常用药物及一些重要的内源性物质。CYP2C9具有高度多态性,迄今为止已发现30个等位基因的单碱基突变。其中具有功能意义的基因突变会影响CYP2C9酶的活性,导致CYP2C9酶底物药物清除率改变,有致药物不良反应或毒性的危险。用药前对CYP2C9基因进行分型,根据患者的基因型调整CYP2C9底物药物的剂量,能提高药物疗效、降低不良反应发生率,实现个体化药物治疗。Cytochrome P450 protein 2C9（CYP2C9）is an essential human liver enzyme for drug metabolism,including 10%of routine drugs used in clinical practice and some crucial endogenous substances.CYP2CP has a high polymorphism as thirty single-base mutations of alleles have been identified until now.Functional mutations may alter the activity of CYP2C9 and the elimination rate of substance drugs.It is subject to the risk of drug adverse effects or toxicity.The genotyping of CYP2C9 prior to the administration helps to adjust the dose of substance drug based on the genotype of patient,improve the drug efficacy,and decrease the incidence of adverse effects in aiming to achieve individualized drug therapy.

关 键 词：细胞色素氧化酶2C9 基因多态性 个体化治疗 

分 类 号：R972[医药卫生—药品]